U.S. flag An official website of the United States government
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. Use of Investigational Tobacco Products
  1. Regulatory Information

GUIDANCE DOCUMENT

Use of Investigational Tobacco Products Guidance for Industry and Investigators February 2019

Draft

Not for implementation. Contains non-binding recommendations.

Use of Investigational Tobacco Products

Docket Number:
FDA-2014-D-1939
Issued by:
Guidance Issuing Office
Center for Tobacco Products

February 2019

pdf icon small Guidance for Industry and Investigators: Use of Investigational Tobacco Products (Revised)*

Section 910(g) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 16 387j(g)) gives FDA the authority to issue regulations to exempt tobacco products intended for investigational use from the requirements of chapter IX of the FD&C Act, including premarket submission requirements. To date, FDA has not issued such regulations; consequently, investigational tobacco products are not exempt from FD&C Act requirements, including premarket submission requirements. This draft guidance supersedes the draft guidance of the same title dated September 2015 and, when final, will describe FDA’s current thinking regarding the definition of investigational tobacco product and discuss the kind of information FDA intends to consider in making enforcement decisions regarding the use of investigational tobacco products until regulations are issued and become effective or FDA provides written notice of its intent to change its enforcement policy.

FDA’s guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidances means that something is suggested or recommended, but not required.


Submit Comments

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Division of Dockets Management (HFA- 305)
Food and Drug Administration
5630 Fishers Lane, Rm. 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2014-D-1939.

Questions?

Contact Point
Contact CTP
Document Control Center
Center for Tobacco Products
Food and Drug Administration
10903 New Hampshire Ave WO71-G335
Silver Spring, MD 20993-002
AskCTP@fda.hhs.gov
(877) 287-1373 (9am EST-4pm EST)